OncologySanofi
Sanofi Reports Phase 3 ICARIA-MM Results for Sarclisa in Multiple Myeloma
BMI
Biotechnology Media Insights
Editorial Team · February 18, 2024
Sanofi announces Phase 3 ICARIA-MM trial results showing isatuximab plus pomalidomide and dexamethasone significantly improves outcomes in relapsed/refractory myeloma.
Sanofi today announced results from the Phase 3 ICARIA-MM trial evaluating Sarclisa (isatuximab) plus pomalidomide and dexamethasone (IPd) versus pomalidomide and dexamethasone (Pd) in patients with relapsed or refractory multiple myeloma. The trial met its primary endpoint, demonstrating a significant improvement in progression-free survival with IPd.
BMI
Biotechnology Media Insights
Published by Biotechnology Media Insights — your trusted source for pharmaceutical, biotech, and life sciences news.